AlphaYou
Overview
Smart money at a glance
Filings to Sep 23, 2026Net buying: insiders sold $0 and bought $10K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- +$10K netNet buying
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
Key stats
Fundamentals Sep 23- 52-wk high
- $2.23
- 52-wk low
- $1.00
- Prev close
- $1.67
- Mkt cap
- $21.4M
- Beta
- 1.65
- P/S
- 0.7x
- P/B
- 0.7x
- Profit margin
- -106.6%
- Op margin
- -88.3%
- ROE
- -83.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about BNGO filings
Are insiders buying or selling Bionano Genomics Inc (BNGO) stock?
Net buying: insiders sold $0 and bought $10K of BNGO stock on the open market in the 90 days to Sep 23, 2026, according to SEC Form 4 filings. The largest was Luderer, Albert (Interim Chief Executive), who bought $10K. The latest filing was on Sep 9, 2026.
Which members of Congress have traded BNGO recently?
None. No member of Congress disclosed a BNGO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this BNGO smart-money data?
This summary uses filings available on Sep 23, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
6 funds hold a position and insiders have been net buying.
What insiders are doing
How top traders are positioned
No tracked top-trader positions in BNGO right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 8.6% above what analysts expected.
Earnings per share
-$0.70 expected
Reports Nov 12, 2026, in 50 days
EPS expected
-$0.42 to -$0.42
Revenue expected
2 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -106.6%
- Market cap
- $21M
Valuation
- P/S0.71
- P/B0.68
Quality
- Operating margin-88.3%
- ROE-83.6%
- ROA-32.6%
Growth
- Beta1.65
Technicals
Price structure
Technicals sync when verified market data is available. No sample data is shown.